Abstract
The role of probiotics on sepsis, particularly when induced by multidrug-resistant (MDR) bacteria, is mediated through complex biochemical pathways. Probiotics demonstrate a capacity to effectively combat infections and reduce mortality rates in sepsis cases. A significant contributor to this efficacy is attributed to the short-chain fatty acids (SCFAs) produced by these probiotics. SCFAs play a critical role in modulating the immune system, primarily by influencing the production of inflammatory cytokines, fortifying the integrity of intestinal epithelium, preventing cellular apoptosis, and maintaining the balance of gut microbiota. Moreover, probiotics are instrumental in counteracting the detrimental impacts of excessive antibiotic use, which is a major contributing factor to the emergence of MDR bacterial strains. The integration of probiotics with conventional therapeutic approaches offers a viable and potentially effective strategy in the management of sepsis caused by MDR bacteria, suggesting a promising direction for future clinical interventions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
